Different to the results of a prior study that visfatin-induced disruption on junction proteins of mouse vascular endothelial cells was conducted through the HMGB1-RAGE rather than the HMGB1-TLR4 pathway (Chen et al., 2015), our results indicate that both TLR4 and RAGE receptor-specific antibodies can inhibit NLRP3 inflammasome activation, platelet activation and thrombocytopenia. The gene discussed is HMGB1; the disease is Thrombocytopenia.